Tumours in the T2 subgroup also had a higher tumour mutation burden (point mutations per Mb) (p-adj ≤ 0.03, Fig. 1f) and harboured 80% of the mutations in mTOR pathway genes (Supplementary Data 1). Here, MTOR is linked to neoplasm.